Paulson & CO. Inc. bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 111,100 shares of the biopharmaceutical company’s stock, valued at approximately $1,424,000. Paulson & CO. Inc. owned 0.08% of Halozyme Therapeutics as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of HALO. Ameritas Investment Partners Inc. bought a new position in Halozyme Therapeutics in the 1st quarter worth about $122,000. Teacher Retirement System of Texas bought a new position in Halozyme Therapeutics in the 2nd quarter worth about $129,000. Arrowstreet Capital Limited Partnership bought a new position in Halozyme Therapeutics in the 2nd quarter worth about $131,000. Prudential Financial Inc. boosted its stake in Halozyme Therapeutics by 8.7% in the 2nd quarter. Prudential Financial Inc. now owns 11,726 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 940 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new position in Halozyme Therapeutics in the 2nd quarter worth about $171,000. Institutional investors and hedge funds own 85.02% of the company’s stock.
Shares of Halozyme Therapeutics, Inc. (NASDAQ HALO) traded up 1.35% during trading on Friday, hitting $17.24. The company had a trading volume of 272,964 shares. The stock’s market capitalization is $2.31 billion. The firm’s 50 day moving average is $16.48 and its 200-day moving average is $13.99. Halozyme Therapeutics, Inc. has a 52 week low of $8.18 and a 52 week high of $18.43.
Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. The firm had revenue of $33.80 million for the quarter, compared to the consensus estimate of $31.76 million. During the same period in the previous year, the company posted ($0.21) earnings per share. Halozyme Therapeutics’s quarterly revenue was up 1.2% on a year-over-year basis. Equities research analysts anticipate that Halozyme Therapeutics, Inc. will post ($0.13) EPS for the current fiscal year.
Several research analysts have commented on HALO shares. Deutsche Bank AG raised their target price on Halozyme Therapeutics to $20.00 and gave the stock a “buy” rating in a research note on Friday, September 15th. Zacks Investment Research upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Friday, August 25th. Piper Jaffray Companies set a $20.00 price target on Halozyme Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 10th. Canaccord Genuity set a $16.00 price target on Halozyme Therapeutics and gave the company a “buy” rating in a research report on Wednesday, July 26th. Finally, BidaskClub downgraded Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, July 1st. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $17.00.
ILLEGAL ACTIVITY WARNING: “Paulson & CO. Inc. Invests $1.42 Million in Halozyme Therapeutics, Inc. (HALO)” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2017/10/27/paulson-co-inc-invests-1-42-million-in-halozyme-therapeutics-inc-halo.html.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.